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by the patient preference to different characteristics of ESA treatments. Patients 
had to complete a questionnaire at baseline and around 6-month. Questionnaire 
was developed using a CBC analysis method with the following hypothesis: 1) 7 
ESA characteristics; 2) from 2 to 3 levels per characteristics; 3) each possible 
answer includes 1 level for 2 characteristics; 4) 2 choices per question; 5) and 6) 7 
questions per CBC questionnaire. The number of combinations between all 
characteristics and levels was 288, and 20 questionnaires have been generated in 
order to mix all possible treatment characteristics and levels. Patients only had 
to answer one questionnaire and a randomization has been used to obtain equal 
number of respondents for each questionnaire. CBC analysis was planned and 
performed for subgroup of patients already receiving ESA or not. RESULTS: A 
total of 790 patients were included, 609 questionnaires were analyzed at 
baseline. Fifty-five percent of patients were already treated by ESA, among them 
the most important characteristic was the planned frequency of administration 
for 31%, followed by the importance of the treatment efficacy for 20%, the pain at 
injection site for 11%. But when asking a direct question to patient on which 
characteristic was the most important, 82% of them answered treatment 
efficacy, 5% for pain at injection site and frequency of injection. Similar results 
were found for ESA naïve patients. CONCLUSIONS: The CBC analysis revealed 
that frequency of injections is underestimated by patients and should be taken 
into account by physicians when choosing an ESA treatment.  
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OBJECTIVES: To explore how fast patients treated for nocturia (waking up  
at night one or more times to void) reported improvement in initial period  
of undisturbed sleep and sleep quality. METHODS: A 3 month randomized, 
controlled, double-blind study at 39 centers in US and Canada comparing 
treatment versus placebo in patients with ≥2 voids/night. The initial period  
of undisturbed sleep was based on patient reported sleep/void diary. Self 
reported sleep quality was assessed by two VAS scales: 1) quality of last night’s 
sleep, and 2) feeling refreshed in the morning. RESULTS: Following 1 week of 
Desmopressin treatment patients on both placebo and drug had an increase in 
undisturbed sleep (women: 81/105 min; men 30/71 min (placebo/treatment, 
respectively)). After 1 month treatment patients slept statistical significantly 
longer (women 95 /131 min, p=0.02; men 56/99 min, p<0.001), increasing to a 3 
month treatment contrast of 49 minutes (women) and 39 minutes (men) and 
with a mean total period of undisturbed sleep of 5.2 hours (women) and 4.3 
hours (men). Patient self reported sleep quality on a 10 point scale increased 
after 1 week (women 1.2 vs. 1.6; men 0.5 vs. 0.7) growing to significant treatment 
difference in women (p= 0.03) and numerical difference in men after 3 months 
(women 1.8 vs. 2.3; men 1.3 vs. 1.7). Self reported feeling of being “refreshed in 
the morning” increased after 1 week (women 1.1 vs. 1.5; men 0.5 vs. 0.7) and was 
statistically significant versus placebo at month 3 (women 1.7 vs. 2.2, p=0.04; 
men 0.85 vs. 1.34, p=0.01). CONCLUSIONS: Treatment increased patients self 
reported initial period of undisturbed sleep already after one week and was 
significantly different from placebo from month 1 and onwards. Patients 
experienced a consequent improvement in sleep quality and feeling refreshed in 
the morning.  
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OBJECTIVES: Traditionally, treatment of nocturia (waking up at night one or 
more times to void) has been focused on a reduction in number of voids. 
However, a serious consequence of nocturia is fragmentation of sleep. Research 
has shown that the initial hours of sleep is fundamental for obtaining the 
necessary amount of slow wave sleep (SWS). METHODS: Data from two 
randomized, placebo-controlled trials (US/Can) with 646 adult patients  
with nocturia (≥2 voids/night determined via 3-day voiding diary) was used. 
Patients were to rate three sleep quality questions on a 10-point visual  
analogue scale during the three months of treatment (baseline, Day 4, Week 1, 
Month 1, 2 and 3): 1) How do you feel right now? 2) Feeling refreshed in the 
morning? and 3) Quality of last night’s sleep? A threshold of 4 hours to time to 
first void (TTFV) (i.e. initial undisturbed sleep) were explored in terms of 
improved scores in the sleep quality questions, by comparing patients in the 
following 4 groups: 1) Poor sleep: TTFV <4 hours at all visits (baseline and post-
baseline); 2) Improved somewhat: Baseline TTFV <4 hours and at least 1 post-
baseline TTFV ≥4 hours; 3) Improved: Baseline TTFV <4 hours, all post-baseline 
TTFV ≥4 hours; and 4) Over threshold at baseline: Baseline TTFV ≥4 hours. 
RESULTS: The change from baseline in all three sleep quality questions were 
statistically and clinically improved for group 2 (Improved somewhat) and even 
further improved for group 3 when comparing with group 1, with significant 
differences already occurring at week 1. The differences widened over the study 
period. The magnitude of improvement was consistently higher for females 
compared to males. CONCLUSIONS: In conclusion, more than 4 hours of 
undisturbed sleep is associated with rapid and clinically meaningful 
improvements in sleep quality for nocturia patients and could be used as a 
future treatment goal.  
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OBJECTIVES: Patient-reported disease burden in Autosomal Dominant Polycystic 
Kidney Disease (ADPKD) has not been rigorously documented. This study 
provides initial evaluation of the psychometric properties of two new ADPKD-
targeted instruments: ADPKD Impact Scale (ADPKD-IS) and ADPKD Urinary 
Impact Scale (ADPKD-UIS). METHODS: US-English versions of ADPKD-IS and 
ADPKD-UIS were administered to 702 adults with ADPKD as part of an 
observational study. Confirmatory factor analysis (CFA) was conducted to test 
the fit of previously developed conceptual frameworks. Next, item response 
theory (IRT) and classical psychometrics were examined, including item- and 
scale-level reliability and convergent validity (with the SF-12v2 and Brief Pain 
Inventory – Short Form (BPI-SF)). RESULTS: CFA results for both instruments 
demonstrated good fit between data and conceptual frameworks (ADPKD-IS 
domains of physical impact, fatigue, and emotional impact and ADPKD-UIS 
domains of urinary urgency burden, urinary frequency burden, and nocturia 
burden): ADPKD-IS = confirmatory fit index (CFI)/nonnormed fit index (NNFI) > 
0.95, root mean square error of approximation (RMSEA) < 0.06; ADPKD-UIS = 
CFI/NNFI > 0.99, RMSEA < 0.08. IRT- and item-level analyses revealed no 
misclassified items with their intended scales or problems with skew or 
inappropriate heterogeneity of variance throughout the response scale. Internal 
consistency reliability for all domains ranged from the mid .80s to mid .90s. 
Convergent validity of the ADPKD-IS/ADPKD-UIS domains was supported by 
correlations with the SF-12 (PCS/MCS) and BPI-SF domains (mid .40s to mid .60s). 
CONCLUSIONS: The ADPKD IS/ADPKD-UIS instruments demonstrated 
prespecified psychometric criteria. Whereas longitudinal evaluation of these 
measures is needed, the current study provides encouraging results for these 
new ADPKD-specific measures of patient burden.  
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OBJECTIVES: To assess the content validity of the Actionable Bladder Symptom 
Screening Tool (ABSST), previously validated in patients with multiple sclerosis 
(MS) associated neurogenic detrusor overactivity (NDO), in women with 
overactive bladder (OAB) and urgency urinary incontinence (UUI). The ABSST is 
an 8-item questionnaire which assesses bladder symptoms along with their 
impact. METHODS: Cognitive interviews were conducted with non-diabetic 
female gynecology patients suffering from OAB and UUI to 1) understand how 
subjects describe experiencing OAB and UUI and, 2) assess subjects’ 
comprehension of the ABSST. Interviews were audio-recorded, transcribed 
verbatim, and analyzed using Atlas.ti. RESULTS: Ten subjects were interviewed; 
6 Caucasian, mean age was 49.2 ± 13.7, and 7 full- or part-time employed. All  
10 subjects had clinician-confirmed and self-reported OAB (average duration 6.9 
± 4.7 years). Mean ABSST score was 4.2 out of 8. Subjects understood the  
5 symptom items (frequencies of urinary urgency, urgency incontinence, 
nocturia, and total micturition, and intensity of urinary urgency) and the 3 
impact items (social limitations, embarrassment, and work limitations) as 
intended including instructions, and response options. Subjects confirmed that 
the symptoms were relevant and important. Although only a few subjects 
spontaneously reported experiencing the symptom impacts, 6 subjects 
acknowledged embarrassment was important and 7 subjects reported 
experiencing work limitations. CONCLUSIONS: Overall, subjects found the 
ABSST items relevant and easy to understand. Participants found the symptom 
items were more relevant than the impact items. Possible explanations may be 
that these gynecology patients are a younger, healthier group compared to the 
MS sample, and have adapted to and coped with their conditions thereby 
lessening the perceived impacts of OAB and UUI. Nonetheless, the ABSST was 
understood well and was reported to be comprehensive and relevant to their 
experiences with OAB and UUI symptoms.  
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OBJECTIVES: Mirabegron, a novel selective beta-3 adrenergic agonist, has 
recently been approved in the United States for the treatment of overactive 
bladder (OAB). This study aimed to assess the impact of mirabegron on Work 
Productivity and Activity Impairment (WPAI) and the associations between WPAI 
outcomes and OAB symptom severity. METHODS: Data were obtained from a 12-
week phase III randomized trial (NCT00662909) comparing mirabegron 50mg and 
placebo for OAB treatment. WPAI outcomes were measured using the WPAI-
Questionnaire for OAB, including employment and total activity impairment 
(TAI) for all patients, and absenteeism, presenteeism and total work productivity 
impairment (TWPI) for employed patients. OAB severity measures included 
